ArticleBreast cancer (Dove Medical Press)2016

Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study.

Shannon Puhalla et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.